Immunotherapy with her-2 and vegf peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer

OncoImmunology

Volumn 1, Issue 7, 2012, Pages 1004-1016

  Foy, Kevin C ^a   Miller, Megan J ^a   Moldovan, Nicanor ^a   Bozanovic, Tatjana ^b   Carson, William E ^c   Kaumaya, Pravin T P ^a,c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Chemoagents epitopes; HER 2 peptide mimics; Immunotherapy; Monoclonal antibodies; Paclitaxel; Peptidomimetics; Toxicity; VEGF peptide mimics

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCYLISOLEUCYLHISTIDYLGLUTAMINYLGLYCYLGLUTAMINYLHISTIDYLPROLYLLYSYLISOLEUCYLARGINYLMETHIONYLISOLEUCINE; ISOLEUCYLMETHIONYLARGINYLISOLEUCYLLYSYLPROLYLHISTIDYLGLUTAMINYLGLYCYLGLUTAMINYLHISTIDYLISOLEUCYLGLYCINE; PACLITAXEL; PROLYLALANYLLEUCYLVALYLTHREONYLTYROSYLASPARAGINYLTHREONYLASPARTYLTHREONYLPHENYLALANYLGLUTAMYLSERYLMETHIONYLPROLYLASPARAGINYLPROLYLGLUTAMYLGLYCYLARGINYLTYROSYLTHREONYLPHENYALANYLGLYCYLLALANYLSERINE; SERYLALANYLGLYCYLPHENYLALANYLTHREONYLTYROSYLARGINYLGLYCYLGLUTAMYLPROLYLASPARAGINYLPROLYLMETHIONYLSERYLGLUTAMYLPHENYLALANYLTHREONYLASPARTYLTHREONYLGLUTAMYLTYROSYLTHREONYLVALYLLEUCYLALANYLPROLINE; SYNTHETIC PEPTIDE; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; MONOTHERAPY; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN STRUCTURE; TRANSGENIC MOUSE; TUMOR VOLUME;

EID: 84865209205     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.21057     Document Type: Article

References (43)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235:177-82; PMID:3798106; http://dx.doi.org/10.1126/science. 3798106.
2. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5:317-28; PMID:15093539; http:// dx.doi.org/10.1016/S1535-6108(04)00083-2.
3. Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 2001; 36:1177-81; PMID:11479851; http://dx.doi.org/10.1053/jpsu.2001.25747.
4. Hoeben A, Landuyt B, Highley MS, Wildiers H, Van Oosterom AT, De Bruijn EA. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev 2004; 56:549-80; PMID:15602010; http://dx.doi. org/10.1124/pr.56.4.3.
5. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990; 5:953-62; PMID:1973830.
6. Li B, Ogasawara AK, Yang R, Wei W, He GW, Zioncheck TF, et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002; 39:1095-100; PMID:12052848; http://dx.doi. org/10.1161/01.HYP.0000018588.56950.7A.
7. Eskens FA, Verweij J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. Eur J Cancer 2006; 42:3127-39; PMID:17098419; http://dx.doi. org/10.1016/j.ejca.2006.09.015.
8. Kaumaya PT, Foy KC, Garrett J, Rawale SV, Vicari D, Thurmond JM, et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and/or recurrent solid tumors. J Clin Oncol 2009; 27:5270-7; PMID:19752336; http://dx.doi. org/10.1200/JCO.2009.22.3883.
9. Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011; 286:13612-25; PMID:21321115; http:// dx.doi.org/10.1074/jbc.M110.216812.
10. Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and antiangiogenic responses in vitro and in vivo. J Biol Chem 2011; 286:13626-37; PMID:21325276; http://dx.doi. org/10.1074/jbc.M110.216820.
11. Foy K, Miller M, Moldovan N, Carson WE, Kaumaya PTP. Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo. OncoImmunology 2012; 1: In press; http://dx.doi.org/10.4161/onci.20708.
12. Browder T, Butterfield CE, Kräling BM, Shi B, Marshall B, O'Reilly MS, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60:1878-86; PMID:10766175.
13. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307:58-62; PMID:15637262; http://dx.doi. org/10.1126/science.1104819.
14. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105:R15-24; PMID:10772661; http:// dx.doi.org/10.1172/JCI8829.
15. Inoue D, Togami K, Shimoike N, Tamura R, Imai Y, Kimura T, et al. [Early diagnosis and successful treatment of catastrophic antiphospholipid syndrome complicated by multiple organ failure]. Nihon Rinsho Meneki Gakkai Kaishi 2010; 33:24-30; PMID:20190507; http://dx.doi.org/10.2177/ jsci.33.24.
16. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006; 5:649-59; PMID:16883303; http://dx.doi.org/10.1038/nrd2089.
17. Goodman M, Ro S, Yamazaki T, Spencer JR, Toy A, Huang Z, et al. Topochemical design of bioactive peptides and peptidomimetics. Bioorg Khim 1992; 18:1375-93; PMID:1363715.
18. Chorev M. The partial retro-inverso modification: a road traveled together. Biopolymers 2005; 80:67-84; PMID:15729688; http://dx.doi.org/10.1002/ bip.20219.
19. Srinivasan M, Gienapp IE, Stuckman SS, Rogers CJ, Jewell SD, Kaumaya PT, et al. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J Immunol 2002; 169:2180-8; PMID:12165548.
20. Xu Y, He B, Wang YJ, Fu Q. [Effect of herceptin combined with Doxorubicin on rat cardiotoxicity]. Ai Zheng 2004; 23:367-71; PMID:15087020.
21. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008; 19:1530-9; PMID:18480068; http://dx.doi.org/10.1093/ annonc/mdn292.
22. Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003; 163:2113-26; PMID:14578209; http://dx.doi. org/10.1016/S0002-9440(10)63568-7.
23. Rovero S, Amici A, Di Carlo E, Bei R, Nanni P, Quaglino E, et al. DNA vaccination against rat her-2/ Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 2000; 165:5133-42; PMID:11046045.
24. Fox WD, Higgins B, Maiese KM, Drobnjak M, Cordon-Cardo C, Scher HI, et al. Antibody to vascular endothelial growth factor slows growth of an androgenindependent xenograft model of prostate cancer. Clin Cancer Res 2002; 8:3226-31; PMID:12374693.
25. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998; 55:5-30; PMID:9463787; http://dx.doi.org/10.2165/00003495-199855010-00002.
26. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989; 9:1165-72; PMID:2566907.
27. Shepard HM, Lewis GD, Sarup JC, Fendly BM, Maneval D, Mordenti J, et al. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J Clin Immunol 1991; 11:117-27; PMID:1679763; http://dx.doi.org/10.1007/ BF00918679.
28. Ryan AJ, Wedge SR. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. Br J Cancer 2005; 92(Suppl 1):S6-13; PMID:15928657; http:// dx.doi.org/10.1038/sj.bjc.6602603.
29. Grothey A. Recognizing and managing toxicities of molecular targeted therapies for colorectal cancer. Oncology 2006; 20(Suppl 10):21-8; PMID:17354514.
30. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992; 89:4285-9; PMID:1350088; http:// dx.doi.org/10.1073/pnas.89.10.4285.
31. Taylor EM, Otero DA, Banks WA, O'Brien JS. Retro-inverso prosaptide peptides retain bioactivity, are stable In vivo, and are blood-brain barrier permeable. J Pharmacol Exp Ther 2000; 295:190-4; PMID:10991978.
32. Fischer PM. The design, synthesis and application of stereochemical and directional peptide isomers: a critical review. Curr Protein Pept Sci 2003; 4:339-56; PMID:14529528; http://dx.doi. org/10.2174/1389203033487054.
33. Fletcher MD, Campbell MM. Partially Modified Retro-Inverso Peptides: Development, Synthesis, and Conformational Behavior. Chem Rev 1998; 98:763-96; PMID:11848914; http://dx.doi.org/10.1021/ cr970468t.
34. Allen SD, Rawale SV, Whitacre CC, Kaumaya PT. Therapeutic peptidomimetic strategies for autoimmune diseases: costimulation blockade. J Pept Res 2005; 65:591-604; PMID:15885118; http://dx.doi. org/10.1111/j.1399-3011.2005.00256.x.
35. Damyanov C, Radoslavova M, Gavrilov V, Stoeva D. Low dose chemotherapy in combination with insulin for the treatment of advanced metastatic tumors. Preliminary experience. J BUON 2009; 14:711-5; PMID:20148468.
36. Nagy B, Molnár J, Rovó L, Paczona R, Thurzó L. [Radiotherapy in combination with low-dose chemotherapy in locally advanced head and neck cancer]. Magy Onkol 2004; 48:145-9; PMID:15351810.
37. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13:12-5; PMID:11863092; http://dx.doi.org/10.1093/annonc/ mdf093.
38. Allen SD, Garrett JT, Rawale SV, Jones AL, Phillips G, Forni G, et al. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007; 179:472-82; PMID:17579068.
39. Sundaram R, Lynch MP, Rawale SV, Sun Y, Kazanji M, Kaumaya PT. De novo design of peptide immunogens that mimic the coiled coil region of human T-cell leukemia virus type-1 glycoprotein 21 transmembrane subunit for induction of native protein reactive neutralizing antibodies. J Biol Chem 2004; 279:24141-51; PMID:15060075; http://dx.doi.org/10.1074/jbc. M313210200.
40. Söll R, Beck-Sickinger AG. On the synthesis of orexin A: a novel one-step procedure to obtain peptides with two intramolecular disulphide bonds. J Pept Sci 2000; 6:387-97; PMID:10969868; http://dx.doi. org/10.1002/1099-1387(200008)6:8<387::AIDPSC267> 3.0.CO;2-M.
41. Dakappagari NK, Lute KD, Rawale S, Steele JT, Allen SD, Phillips G, et al. Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities. J Biol Chem 2005; 280:54-63; PMID:15507452.
42. Chiesa-Vottero AG, Malpica A, Deavers MT, Broaddus R, Nuovo GJ, Silva EG. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 2007; 26:328-33; PMID:17581420; http:// dx.doi.org/10.1097/01.pgp.0000235065.31301.3e.
43. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988; 44:1049-60; PMID:3233245; http:// dx.doi.org/10.2307/2531734.